Without digging deeper , the PR doesn't give enough info to say whether this is a signif advance over BNP and NT-proBNP testing. Indeed, the PR doesn't even say whether the two tests have gone head to head in a trial.
There sure doesn't seem to be any likelihood of near term good news priced into Response the way it is trading lately.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.